Exelixis and Ipsen to Host Investor and Media Briefing to Discuss Data Presented at the ESMO 2016 Congress

On October 3, 2016 Exelixis, Inc. (NASDAQ:EXEL) reported that the company and its partner Ipsen will jointly host a live investor and media briefing at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2016 Congress (Press release, Exelixis, OCT 3, 2016, View Source;p=RssLanding&cat=news&id=2208613 [SID:SID1234515574]). The event will be held on Monday, October 10, 2016, with the program beginning at 19:00 CEST (local Copenhagen time) / 1:00 p.m. EDT / 10:00 a.m. PDT following on-site registration starting at 18:30 CEST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the briefing, Exelixis and Ipsen management and invited guests will discuss and provide context for clinical data for cabozantinib presented at the ESMO (Free ESMO Whitepaper) 2016 Congress. Key topics will include CABOSUN, the randomized phase 2 trial of cabozantinib compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, which will be the subject of a late-breaking oral presentation during ESMO (Free ESMO Whitepaper)’s Presidential Symposium 3 earlier in the day. Presenters will also review data from the ongoing phase 1b trial evaluating the combination of cabozantinib and nivolumab in patients with genitourinary tumors.

The briefing will also be webcast live and available via conference call starting at 19:00 CEST / 1:00 p.m. EDT / 10 a.m. PDT on Monday, October 10. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company’s website at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be required to listen to the event. To participate by phone, please dial 855-299-5224 (domestic) or 631-267-4890 (international/toll dial) and use passcode 234-026-024. Please see the Event Calendar page for details on replay options once available.